New agitation drug igalmi tested for repeated use in mental health conditions

NCT ID NCT06041646

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 4 times

Summary

This completed study tested Igalmi, a fast-dissolving film placed under the tongue, for managing frequent agitation in people with schizophrenia or bipolar disorder. 29 adults received the drug as needed for 7 days in a clinic. Researchers looked for signs that the drug might stop working over time (tolerance) or cause withdrawal symptoms when stopped. The goal was to understand how safe and effective repeated use is for calming agitation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Igalmi (dexmedetomidine) sublingual film
What this could lead to
If successful, this could help doctors understand how to use Igalmi safely for repeated agitation episodes without losing effectiveness or causing withdrawal.
What could go wrong
This is a small, early-phase study with only 29 participants and no comparison group. Results may not apply to all patients, and side effects like rapid heart rate or nausea are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGITATION,PSYCHOMOTOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • BioXcel Clinical Research Site

    Little Rock, Arkansas, 72211, United States

  • BioXcel Clinical Research Site

    Rogers, Arkansas, 72758, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.